ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the trademark for the Company's patented HemoPalm technology has been allowed by the United States Patent and Trademark Office and will be officially registered when the HemoPalm is released commercially.
http://bit.ly/1shXZJO
No comments:
Post a Comment